Meldungen zum Thema Medizinische Behandlung

Johnson & Johnson MedTech

Personalized Treatment Plans Influence European Public's Willingness to Share Health Data

Leeds, England (ots/PRNewswire) - A global survey reveals Europe's growing confidence in the use of data and technology to transform healthcare and surgery. A global survey from Johnson & Johnson MedTech, a global leader in cardiovascular, orthopaedic, surgery and vision solutions, reveals that Europeans are favorable to sharing their health data in exchange for ...

Acousia Therapeutics GmbH

Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study

Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...

Helmholtz Munich

Engineering Smart Delivery for Gene Editors

PNO Innovation GmbH

SGLT2 HYPE: New EU-funded Project Aims to Transform Hypertension Treatment

GEA Group Aktiengesellschaft

2

GEA presents the kytero® 10, the world's smallest single use disk stack centrifuge

STADA Arzneimittel AG

3

Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market

Grünenthal Group

Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal

Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...

CO.DON GmbH

CO.DON GmbH partners in EU-Funded Project to Advance 3D Bioprinting for Tissue Regeneration

Teltow (ots) - The EU-funded micro2MACRO (m2M) project, launched in December 2024, aims to advance tissue regeneration through an innovative bioprinting platform. m2M focuses on precisely patterning cell aggregates and microtissues into stable, customizable grafts that remodel into functional tissues after implantation. The project unites leading academic institutions, ...

Norgine GmbH

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...

Helmholtz Munich

SCP-Nano: A New Technology to Visualize Nanocarriers in Cells and Tissues

Norgine GmbH

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma

London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...

RHEACELL GmbH und Co. KG

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Gerresheimer AG

Gerresheimer: FDA grants Tentative Approval of SQ Innovation’s Lasix® ONYU*

Technische Universität München

Complex pancreatic tumor organoids as foundation for new treatment strategies

TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Foundation for new cancer treatment strategies Organoids represent the complex cell landscape of pancreatic cancer - Tumors are composed of cancer cells with a variety of different characteristics. - This contributes significantly to the complexity of pancreatic cancer and makes the disease difficult to treat. - For the ...

European Alliance Against Depression

First European Patient Congress Depression for those affected by depression and their close relations takes place online on December 7, 2024 / Free online-event offers information and experience-sharing

Frankfurt am Main (ots) - The European Patient Congress Depression, hosted by the European Alliance Against Depression (EAAD), will take place on December 7, 2024. This free online-event is designed to support individuals affected by depression and their relatives, providing a platform for expert guidance, patient ...

Helmholtz Munich

Inceptor Regulates Insulin Homeostasis: A New Approach for Diabetes Therapies

Grünenthal Group

Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain

Aachen, Germany/Morristown, N.J. (ots) - - The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures ...

Ottobock SE & Co. KGaA

Ottobock invests in NeuroTech company ONWARD® Medical

Grünenthal Group

First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist

Aachen, Germany (ots) - Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the ...

STADA Arzneimittel AG

Press Release: EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar

EMA accepts Marketing Authorization Applications for AVT03, a Proposed Denosumab Biosimilar - STADA announces EMA acceptance of Marketing Authorization Applications for AVT03, a proposed denosumab biosimilar to Prolia® (Bone Health) and Xgeva® (Oncology) - STADA holds marketing rights for AVT03 in Europe, as well ...

Asclea GmbH

Successful MDR Certification for AI Solution in Predicting Postoperative Complications – New Product Generation for Optimized Patient Safety

Berlin (ots) - x-cardiac, a leader in AI-based medical devices for the prediction of postoperative complications after cardiac surgery, is pleased to announce the successful MDR (Medical Device Regulation) certification of its new x-cardiac-platform. This certification introduces a completely new generation of ...

RHEACELL GmbH und Co. KG

RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU

Fördergesellschaft IZB mbH

2

Record financing rounds at the Munich biotech hub

ARTCLINE GmbH

ARTCLINE successfully completes capital increases of EUR 4.4 million

Rostock, Germany (ots) - Today ARTCLINE GmbH announced the successful completion of two further capital increases. In addition to the founders, in particular family offices from Germany participated in the first capital increase of EUR 0.8 million. In addition, a convertible loan from investors was transferred to equity, so that a second capital increase of EUR 3.6 ...